Objectives: Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemic and the impact of prevention strategies. Although several laboratory-based tests have been developed strictly for this purpose, several limitations exist and improved methods or technologies are needed. We sought to further optimize a previously described bead-based, HIV-1-specific multiplex assay with the capability of measuring multiple immune responses for determining recent infection. Methods: We refined the customized HIV-1 Bio-Plex assay by determining cutoffs and mean durations of recency (MDR), based on the reactivity to longitudinal seroconversion specimens (n = 1347) from 311 ART-naı̈ve, HIV-1-infected subjects. False-...
BackgroundGiven the challenges and costs associated with implementing HIV-1 incidence assay testing,...
Recent-infection testing assays/algorithms (RITAs) have been developed to exploit the titer and avid...
This is the official assay evaluation report on Sedia Biosciences Corporation's Asanté™ HIV-1 Rapid ...
Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemi...
Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemi...
BACKGROUND:Accurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence f...
Accurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence from cross-s...
BackgroundAccurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence fr...
OBJECTIVE:HIV seroconversion biomarkers are being used in cross-sectional studies for HIV incidence ...
<div><p>Background</p><p>Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cros...
The incidence of human immunodeficiency virus (HIV) is the rate at which new HIV infections occur in...
A limiting antigen avidity enzyme immunoassay (HIV-1 LAg-Avidity assay) was recently developed for c...
Laboratory-based HIV tests for recent infection (TRIs), which primarily measure a specific serologic...
<p>Study samples were initially designated as HIV NEG, HIV DISC, and HIV POS based on HIV rapid test...
The incidence of human immunodeficiency virus (HIV) is the rate at which new HIV infections occur in...
BackgroundGiven the challenges and costs associated with implementing HIV-1 incidence assay testing,...
Recent-infection testing assays/algorithms (RITAs) have been developed to exploit the titer and avid...
This is the official assay evaluation report on Sedia Biosciences Corporation's Asanté™ HIV-1 Rapid ...
Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemi...
Accurate methods of estimating HIV-1 incidence are critical for monitoring the status of the epidemi...
BACKGROUND:Accurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence f...
Accurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence from cross-s...
BackgroundAccurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence fr...
OBJECTIVE:HIV seroconversion biomarkers are being used in cross-sectional studies for HIV incidence ...
<div><p>Background</p><p>Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cros...
The incidence of human immunodeficiency virus (HIV) is the rate at which new HIV infections occur in...
A limiting antigen avidity enzyme immunoassay (HIV-1 LAg-Avidity assay) was recently developed for c...
Laboratory-based HIV tests for recent infection (TRIs), which primarily measure a specific serologic...
<p>Study samples were initially designated as HIV NEG, HIV DISC, and HIV POS based on HIV rapid test...
The incidence of human immunodeficiency virus (HIV) is the rate at which new HIV infections occur in...
BackgroundGiven the challenges and costs associated with implementing HIV-1 incidence assay testing,...
Recent-infection testing assays/algorithms (RITAs) have been developed to exploit the titer and avid...
This is the official assay evaluation report on Sedia Biosciences Corporation's Asanté™ HIV-1 Rapid ...